Australian Team Develops Nasal mRNA Alzheimer’s Therapy, Mouse Tests Show Cognitive Benefit
The liquid drug, delivered one drop at a time into the nostrils, carries instructions for making a brain protein called BDNF inside the same lipid nanoparticles used in COVID-19 vaccines, according to BigGo 財經.
It is the first time this mRNA platform has been applied to a neurological disease. The findings were published in the international journal Advanced Science.
In aged mice, treatment improved the ability to remember locations and to tell new objects from familiar ones, and increased the number of nerve cells in the hippocampus, the brain’s memory center. In mice genetically modified to show Alzheimer’s symptoms, the same treatment stopped memory loss from taking hold.
Those model mice show dementia-like brain pathology from two months of age — roughly the late teenage years in human terms — and measurable cognitive decline by four months, comparable to a person in their early twenties. Treated twice weekly starting at two months, they showed no cognitive deterioration at four months.
- Treated mice avoided the memory decline seen in untreated Alzheimer’s model animals, and the therapy worked without reducing amyloid-beta plaques.
- The results are limited to animal studies; the team plans human clinical trials within two years.
Why BDNF matters in Alzheimer’s
BDNF, or brain-derived neurotrophic factor, helps nerve cells survive and sustains learning and memory. In people with Alzheimer’s disease, concentrations of the protein fall sharply in the hippocampus and the entorhinal cortex, the two regions hit earliest by the disease’s pathogenesis. The therapy’s premise is to restore that supply directly.
The nose route solves a delivery problem that has long constrained neurology. Large protein drugs cannot cross the blood-brain barrier — the layer of endothelial cells lining brain blood vessels that admits oxygen and nutrients but blocks bigger molecules. Rather than injecting protein into the bloodstream, the team treats the nasal mucosa as a protein-manufacturing site, sending the freshly made BDNF straight toward the brain.
Results independent of amyloid-beta
A telling detail sits in the plaque data. Amyloid-beta, the protein widely treated as a driver of Alzheimer’s, normally protects nerve cells but damages them once it clumps. The mRNA-generated BDNF did not reduce amyloid-beta plaques in the treated mice — yet preserved brain function anyway.
The team framed the approach as complementary rather than competing with the anti-amyloid antibody drugs that dominate the current market, saying the two methods could produce a synergistic effect. Standard-of-care antibody therapies target the protein aggregates; this one supports the nerve cells themselves, opening a separate therapeutic path.
“This research demonstrates that mRNA therapy has the potential to extend from infectious disease into the treatment of neurological disease.”
said Dr. Maria Bergamasco, the paper’s first author.
“In the future it could be used not only for older adults, but could also raise cognitive ability in healthy young people.”
said Professor Greg Neely, who led the team, adding that the approach could apply to a range of degenerative neurological diseases.
Human trials planned within two years
The jump from mice to people is not automatic. Mouse and human nasal structures differ, the team acknowledged, making human clinical trials necessary. It plans to begin those trials within two years.
Until then, the work remains at the animal-experiment stage, with commercialization still a considerable distance off. If pharmaceutical manufacturers move into mRNA drugs for brain disease, the report anticipated knock-on effects for platform technologies and the lipid nanoparticle delivery-carrier market.
For patients and families following Alzheimer’s research, the practical picture is unchanged for now: approved treatments remain the current standard, and families weighing emerging therapies or cognitive symptoms can consult board-certified neurologists and memory-disorder specialists about what evidence supports each option. The next concrete milestone on record is the planned start of clinical trials, which the team dates to within two years.
The findings appeared in Advanced Science, an interdisciplinary peer-reviewed open-access journal published by Wiley-VCH since 2014 and edited by Kirsten Severing. The journal, based in Germany, covers materials science, physics and chemistry, medical and life sciences, and engineering, and holds a 2025 impact factor of 14.1 according to the Journal Citation Reports, placing it in the top quartile of its indexed categories.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.
Related reading